Moreover, this drug combination attenuates cytoprotective RAS/RAF/MAPK/ERK and STAT5 signaling in CML-BC cells, and correlates with decreased expression of STAT5 target genes related to proliferation and cytoprotection. The gene discussed is MAPK1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.